Share This Author
Psychometric properties of the Multidimensional Scale of Perceived Social Support in youth.
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study
The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
- N. Schooler, J. Rabinowitz, G. de Smedt
- Psychology, MedicineThe American journal of psychiatry
- 1 May 2005
Relatively low doses of antipsychotic drugs lead to significant symptom amelioration in the majority of first-episode psychosis patients and in the long term, risperidone prevents relapse in more patients and for a longer time and also induces less abnormal movements than haloperidol.
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.
- R. Emsley, C. Myburgh, P. Oosthuizen, S. V. van Rensburg
- Medicine, PsychologyThe American journal of psychiatry
- 1 September 2002
EPA may be an effective and well-tolerated add-on treatment in schizophrenia.
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.
The data suggest that olanzapine does not differ from haloperidol in achieving overall remission of bipolar mania, however, hal operidol carries a higher rate of extrapyramidal symptoms, whereas olanZapine is associated with weight gain.
Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group.
- R. Emsley
- Psychology, MedicineSchizophrenia bulletin
The severity of extrapyramidal symptoms and the use of antiparkinsonian medications were significantly lower in patients receiving low doses of risperidone or haloperidol than high doses of these antipsychotics.
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies
- R. Emsley, J. Berwaerts, J. Palumbo
- Medicine, PsychologyInternational clinical psychopharmacology
- 1 November 2008
This analysis shows that paliperidone extended-release can maintain improvements in symptoms and functioning and is generally well tolerated for up to 52 weeks in schizophrenia patients.